文献速递糖尿病

艾塞那肽联合吡格列酮对比基础/餐时胰岛素治疗HbA1c极高2型糖尿病患者的疗效

Efficacy of Exenatide Plus Pioglitazone Vs Basal/Bolus Insulin in T2DM Patients With Very High HbA1c.
PubMed 文献 · J Clin Endocrinol Metab · 2017-01-01

在卡塔尔研究(Qatar Study)中,101例接受最大或接近最大剂量磺脲类联合二甲双胍、血糖控制极差(HbA1c>10%)且病程长(10.9年)的2型糖尿病患者随机接受吡格列酮联合每周一次艾塞那肽(联合治疗)或基础加餐时胰岛素(胰岛素治疗),目标HbA1c<7.0%。6个月时联合治疗组HbA1c从基线11.5%±0.2%降至6.7%±0.1%(∆=-4.8%),胰岛素治疗组从11.2%±0.2%降至7.4%±0.1%(∆=-3.8%)。联合治疗降低HbA1c不受性别、种族或体重指数影响;胰岛素治疗组体重增加显著更多,低血糖发生率是联合治疗组的2.5倍。

要点

  • 艾塞那肽联合吡格列酮使HbA1c从11.5%±0.2%降至6.7%±0.1%(∆=-4.8%),胰岛素治疗组从11.2%±0.2%降至7.4%±0.1%(∆=-3.8%)。
  • 联合治疗降低HbA1c的疗效不受性别、种族或体重指数影响。
  • 胰岛素治疗组体重增加显著更多,低血糖发生率是联合治疗组的2.5倍。

核心结论

  • 艾塞那肽联合吡格列酮治疗对接受二甲双胍联合磺脲类且HbA1c极高(>10%)的血糖控制不佳2型糖尿病患者是有效且安全的治疗选择。

研究设计与样本

  • 卡塔尔研究(Qatar Study)随机对照研究,101例血糖控制极差(HbA1c>10%)且病程长(10.9年)的2型糖尿病患者,随机接受吡格列酮联合每周一次艾塞那肽(联合治疗)或基础加餐时胰岛素(胰岛素治疗),目标HbA1c<7.0%。

主要发现

  • 基线HbA1c在联合治疗组为11.5%±0.2%,在胰岛素治疗组为11.2%±0.2%(P=无显著性差异)。
  • 6个月时联合治疗组HbA1c降至6.7%±0.1%(∆=-4.8%),胰岛素治疗组降至7.4%±0.1%(∆=-3.8%)。
  • 联合治疗降低HbA1c不受性别、种族或体重指数影响。
  • 胰岛素治疗组体重增加显著更多,低血糖发生率是联合治疗组的2.5倍。

关键数值与推荐

  • 联合治疗组6个月HbA1c为6.7%±0.1%(∆=-4.8%),胰岛素治疗组为7.4%±0.1%(∆=-3.8%)。
  • 胰岛素治疗组低血糖发生率是联合治疗组的2.5倍。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine the efficacy and safety of combination therapy with exenatide plus pioglitazone vs basal/bolus insulin in patients with poorly controlled type 2 diabetes mellitus (T2DM) with very high hemoglobin A1c (HbA1c) (>10%) receiving sulfonylurea plus metformin and with a long duration of disease. DESIGN AND PARTICIPANTS: Participants (n = 101) in the Qatar Study with very poor glycemic control (HbA1c >10%) and a long duration of diabetes (10.9 years) receiving maximum/near-maximum doses of sulfonylurea plus metformin were randomly assigned to receive pioglitazone plus weekly exenatide (combination therapy), or basal plus prandial insulin (insulin therapy), to maintain HbA1c <7.0%. RESULTS: Baseline HbA1c was 11.5% ± 0.2% and 11.2% ± 0.2% (P = not significant) in combination therapy and insulin therapy groups, respectively. At 6 months, combination therapy caused a robust decrease in HbA1c to 6.7% ± 0.1% (∆ = -4.8%) compared with 7.4% ± 0.1% (∆ = -3.8%) in subjects receiving insulin therapy. Combination therapy was effective in lowering the HbA1c independent of sex, ethnicity, or body mass index. Subjects in the insulin therapy group experienced significantly greater weight gain and a 2.5-fold higher rate of hypoglycemia compared with patients receiving combination therapy. CONCLUSION: Exenatide/pioglitazone combination therapy is an effective and safe therapeutic option in patients with poorly controlled T2DM receiving metformin plus sulfonylurea with very high HbA1c (>10%).

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Abdul-Ghani M, Migahid O, Megahed A, et al. Efficacy of Exenatide Plus Pioglitazone Vs Basal/Bolus Insulin in T2DM Patients With Very High HbA1c. J Clin Endocrinol Metab. 2017. PMID: 28324038. doi:10.1210/jc.2016-3423

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。